---
title: "CUTIA-B: CU-40102 China Phase III clinical trial results accepted for presentation in electronic poster format at the 8th Chinese Medical Association Hair Academic Conference"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/212857799.md"
description: "CUTIA-B announced that the Phase III clinical trial results of its product CU-40102 for treating androgenetic alopecia have been accepted for presentation at the 8th National Hair Conference of the Chinese Medical Association. This product is the world's first topically applied finasteride approved for this condition. Data shows that the efficacy of the CU-40102 group after 24 weeks is significantly better than the placebo group, with good safety and no serious adverse events. The NDA for CU-40102 has also been accepted by the National Medical Products Administration"
datetime: "2024-08-29T04:06:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/212857799.md)
  - [en](https://longbridge.com/en/news/212857799.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/212857799.md)
---

# CUTIA-B: CU-40102 China Phase III clinical trial results accepted for presentation in electronic poster format at the 8th Chinese Medical Association Hair Academic Conference

According to the news from Zhitong Finance and Economics APP, CUTIA-B (02487) announced that the Group's clinical trial results of CU-40102 (topical finasteride spray) for the treatment of androgenetic alopecia in China Phase III were accepted and presented in electronic poster format at the 8th National Hair Conference of the Chinese Medical Association.

CU-40102 is the world's first and only topical finasteride product approved for the treatment of androgenetic alopecia, as well as the first topical finasteride product to be accepted for NDA review by the National Medical Products Administration (NMPA) in China. The Phase III registration clinical trial of CU-40102 in China is a multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of CU-40102 in Chinese adult male patients with androgenetic alopecia.

The results of this clinical trial showed that in terms of efficacy, after 24 weeks of treatment, the total hair count and terminal hair count improvement in the target area of the crown in the CU-40102 group were significantly better than those in the placebo group, with statistically significant differences (P <0.05), meeting the primary endpoint and major secondary endpoints, with efficacy starting to show from the 12th week. In addition, the effective rate of crown hair assessment by researchers showed that after 24 weeks of treatment, the CU-40102 group was significantly better than the placebo group, with statistically significant differences (P <0.05).

In terms of safety, the local tolerability of the administration site in CU-40102 subjects was good, with a similar overall incidence of adverse events between the CU-40102 group and the placebo group, no serious adverse events (TESAE) occurred, and no adverse events leading to death (TEAE).

The NDA for CU-40102 has been accepted by the NMPA

### Related Stocks

- [02487.HK](https://longbridge.com/en/quote/02487.HK.md)

## Related News & Research

- [Cutia Wins NMPA Nod for Topical Anesthesia Cream, Expanding China Dermatology Portfolio](https://longbridge.com/en/news/285457203.md)
- [Vitamin E TPGS ─ Emerging Applications in Novel Parenteral Drug Delivery Systems](https://longbridge.com/en/news/285697906.md)
- [CIRC unit CNGT signs neutron dosimetry lab technical services contract with Pondpol](https://longbridge.com/en/news/285743579.md)
- [Shenzhen Han's CNC declares final dividend of RMB 6 per 10 shares](https://longbridge.com/en/news/285730878.md)
- [SEDD introduces instant industrial licence at Make it in the Emirates 2026](https://longbridge.com/en/news/285095057.md)